The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment
Abstract Ovarian cancer is a common malignant tumor in women, exhibiting a certain sensitivity to chemotherapy drugs like gemcitabine (GEM). This study, through the analysis of ovarian cancer single-cell RNA sequencing (scRNA-seq) data and transcriptome data post-GEM treatment, identifies the pivota...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01723-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559387429142528 |
|---|---|
| author | Liangliang Wang Shanshan Ma Huiwen Su Dandan Nie Lihua Wang |
| author_facet | Liangliang Wang Shanshan Ma Huiwen Su Dandan Nie Lihua Wang |
| author_sort | Liangliang Wang |
| collection | DOAJ |
| description | Abstract Ovarian cancer is a common malignant tumor in women, exhibiting a certain sensitivity to chemotherapy drugs like gemcitabine (GEM). This study, through the analysis of ovarian cancer single-cell RNA sequencing (scRNA-seq) data and transcriptome data post-GEM treatment, identifies the pivotal role of hypoxia-inducible factor 1 alpha (HIF-1α) in regulating the treatment process. The results reveal that HIF-1α modulates the expression of VEGF-B, thereby inhibiting the fibroblast growth factor 2 (FGF2)/FGFR1 signaling pathway and impacting tumor formation. In vitro experiments validate the mechanistic role of HIF-1α in GEM treatment, demonstrating that overexpression of HIF-1α reverses the drug's effects on ovarian cancer cells while silencing fibroblast growth factor receptor 1 (FGFR1) can restore treatment efficacy. These findings provide essential molecular targets and a theoretical foundation for the development of novel treatment strategies for ovarian cancer in the future. |
| format | Article |
| id | doaj-art-b52ae4a4af09465293068a7149e13202 |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-b52ae4a4af09465293068a7149e132022025-01-05T12:34:24ZengSpringerDiscover Oncology2730-60112025-01-0116111610.1007/s12672-024-01723-5The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatmentLiangliang Wang0Shanshan Ma1Huiwen Su2Dandan Nie3Lihua Wang4Department of Oncology and Gynecology, The First Affiliated Hospital of Bengbu Medical UniversityDepartment of Oncology and Gynecology, The First Affiliated Hospital of Bengbu Medical UniversityDepartment of Oncology and Gynecology, The First Affiliated Hospital of Bengbu Medical UniversityDepartment of Oncology and Gynecology, The First Affiliated Hospital of Bengbu Medical UniversityDepartment of Oncology and Gynecology, The First Affiliated Hospital of Bengbu Medical UniversityAbstract Ovarian cancer is a common malignant tumor in women, exhibiting a certain sensitivity to chemotherapy drugs like gemcitabine (GEM). This study, through the analysis of ovarian cancer single-cell RNA sequencing (scRNA-seq) data and transcriptome data post-GEM treatment, identifies the pivotal role of hypoxia-inducible factor 1 alpha (HIF-1α) in regulating the treatment process. The results reveal that HIF-1α modulates the expression of VEGF-B, thereby inhibiting the fibroblast growth factor 2 (FGF2)/FGFR1 signaling pathway and impacting tumor formation. In vitro experiments validate the mechanistic role of HIF-1α in GEM treatment, demonstrating that overexpression of HIF-1α reverses the drug's effects on ovarian cancer cells while silencing fibroblast growth factor receptor 1 (FGFR1) can restore treatment efficacy. These findings provide essential molecular targets and a theoretical foundation for the development of novel treatment strategies for ovarian cancer in the future.https://doi.org/10.1007/s12672-024-01723-5Ovarian cancerGemcitabineHypoxia-inducible factor 1 alphaVascular endothelial growth factor BFibroblast growth factor 2Fibroblast growth factor receptor 1 |
| spellingShingle | Liangliang Wang Shanshan Ma Huiwen Su Dandan Nie Lihua Wang The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment Discover Oncology Ovarian cancer Gemcitabine Hypoxia-inducible factor 1 alpha Vascular endothelial growth factor B Fibroblast growth factor 2 Fibroblast growth factor receptor 1 |
| title | The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment |
| title_full | The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment |
| title_fullStr | The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment |
| title_full_unstemmed | The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment |
| title_short | The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment |
| title_sort | molecular mechanism of gemcitabine in inhibiting the hif 1α vegfb fgf2 fgfr1 signaling pathway for ovarian cancer treatment |
| topic | Ovarian cancer Gemcitabine Hypoxia-inducible factor 1 alpha Vascular endothelial growth factor B Fibroblast growth factor 2 Fibroblast growth factor receptor 1 |
| url | https://doi.org/10.1007/s12672-024-01723-5 |
| work_keys_str_mv | AT liangliangwang themolecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT shanshanma themolecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT huiwensu themolecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT dandannie themolecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT lihuawang themolecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT liangliangwang molecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT shanshanma molecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT huiwensu molecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT dandannie molecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment AT lihuawang molecularmechanismofgemcitabineininhibitingthehif1avegfbfgf2fgfr1signalingpathwayforovariancancertreatment |